# Safety and Pharmacology Study of BMS-866949

> **NCT01124344** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 47 (actual)

## Conditions studied

- Major Depression

## Interventions

- **DRUG:** Placebo
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949
- **DRUG:** BMS-866949

## Key facts

- **NCT ID:** NCT01124344
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124344, "Safety and Pharmacology Study of BMS-866949". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01124344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*